Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, Inc. (NYSE: AVTR) announced the automatic conversion of its 6.250% Series A Mandatory Convertible Preferred Stock into common stock on May 16, 2022. Each share of Preferred Stock will convert into 3.0395 shares of common stock, with cash paid for any fractional shares. Holders of record as of May 1, 2022 will also receive a final quarterly cash dividend of $0.78 per share payable on the conversion date.
Avantor, Inc. (NYSE: AVTR) has elected Jonathan Peacock, 64, as the new chairman of its board of directors, effective after the annual stockholder meeting today. Peacock succeeds Raj Gupta, who is retiring. Peacock, a board member since 2017, highlighted the company's potential for growth and scientific breakthroughs. He has extensive experience, having held leadership roles at Amgen and Novartis. Avantor is a global provider of mission-critical products and services for life sciences and advanced technologies, serving over 225,000 customers in more than 180 countries.
Avantor (NYSE: AVTR) has partnered with Cytovance Biologics to enhance plasmid DNA development for biopharma clients. This collaboration will leverage Cytovance's cGMP manufacturing capabilities, significantly boosting Avantor's offerings in the rapidly growing gene therapy sector. As demand for therapeutic biologics rises, this partnership is positioned to support increased manufacturing capacity and meet the needs of emerging mRNA and viral vector therapies. Both companies aim to expand their global reach and provide critical materials for research and commercialization.
Avantor, Inc. (NYSE: AVTR) announced on May 5, 2022, the establishment of a new manufacturing and distribution hub in Singapore. This hub aims to enhance supply chain capabilities and better serve the burgeoning Asia Pacific Biopharma market. Integrating existing facilities with new manufacturing operations, the hub will boost regional innovation and deliver services such as quality control and testing labs, becoming operational early next year. This strategic move highlights Avantor's commitment to expanding in Asia and improving lead times and supply chain security.
Avantor reported financial results for Q1 2022, highlighting net sales of $1.95 billion, a 9.2% increase year-over-year. The company achieved organic net sales growth of 5.1% and net income of $190.4 million, up from $164 million in Q1 2021. Adjusted EBITDA rose 16.5% to $423.1 million, with an Adjusted EBITDA margin of 21.7%. Operating cash flow was $152.2 million and free cash flow was $127.7 million. The company also reduced adjusted net leverage to 4.0X, aligning with its long-term target.
Avantor, Inc. (NYSE: AVTR) has declared a quarterly cash dividend of $0.78 per share on its 6.250% Series A Mandatory Convertible Preferred Stock, with a liquidation preference of $50. This dividend will be payable on May 15, 2022 to shareholders on record as of May 1, 2022. The company is a prominent global provider to multiple industries including life sciences and applied materials, serving over 225,000 customer locations in more than 180 countries.
Avantor, a global provider of critical products and services, is set to release its first quarter 2022 financial results after market close on April 28, 2022. The company will host a conference call on April 29, 2022, at 7:30 AM EDT to discuss the results. Investors can join via phone or access the live webcast through Avantor's investors section on its website. A replay of the call will be available until May 29, 2022.
Avantor (NYSE: AVTR), a leading global provider of mission-critical products, announced its participation in the KeyBanc Life Sciences and Medtech Investor Forum on March 22, 2022. Dr. Ger Brophy, Executive Vice President of Biopharma Production, will discuss the company’s business priorities in a fireside chat at approximately 2:15 p.m. EDT. A live webcast will be available on Avantor's website, with a replay accessible until April 22, 2022.
Avantor (NYSE: AVTR) is set to participate in the Barclays Global Healthcare Conference 2022 on March 15. Tom Szlosek, the Executive Vice President and CFO, will present in a fireside chat starting at 8:00 a.m. EDT. A live webcast of the event will be available on Avantor's investors section, with a replay accessible until April 15.
Avantor is a leading global provider in life sciences and advanced technologies, serving over 225,000 customer locations across more than 180 countries.
Avantor (NYSE: AVTR), a key player in mission-critical products for life sciences and advanced technologies, will participate in the 42nd Annual Cowen Healthcare Conference on March 7, 2022. CEO Michael Stubblefield is set to discuss the company's priorities in a fireside chat at 9:10 a.m. EST. The conversation will be available via a live webcast, with a replay accessible until April 7, 2022.
Avantor serves over 225,000 customer locations across more than 180 countries, playing a vital role in research and production within the biopharma and healthcare sectors.